41 filings
Page 2 of 3
8-K
vlvqx0bugmz oqoxo4
7 Aug 19
Constellation Pharmaceuticals Announces Second-Quarter andSix-Month 2019 Financial Results
4:11pm
8-K
ugv0u9j
19 Jun 19
Entry into a Material Definitive Agreement
4:12pm
8-K
n3bcw8jfqdiiwxnjflj
10 Jun 19
Submission of Matters to a Vote of Security Holders
4:35pm
8-K
b5o2biwdoit7mpx
16 May 19
Constellation Pharmaceuticals Provides Interim Update of Data forCPI-0610 in ASCO and EHA Abstracts
9:01am
8-K
phgmauc swog
15 May 19
2019 ASCO Annual Meeting
5:01pm
8-K
zazcbls
8 May 19
Constellation Pharmaceuticals Announces First-Quarter 2019 Financial Results
4:21pm
8-K
5n2o4fezznx
1 Apr 19
Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial ofCPI-1205 at AACR Meeting
1:00pm
8-K
gq90 08ty
21 Mar 19
Entry into a Material Definitive Agreement
6:40am
8-K
q64ezljyki6fe94
14 Mar 19
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2018 Financial Results
5:30pm
8-K/A
9ht4ylw 2iin9fw3
13 Mar 19
Departure of Directors or Certain Officers
4:18pm
8-K
tfgcl
20 Feb 19
Announces Appointment to Board of
7:12am
8-K
nm81xvg6
7 Jan 19
Regulation FD Disclosure
6:39am
8-K
2kwac2vpdrzp
3 Jan 19
Regulation FD Disclosure
7:10am
8-K/A
8ad80t5ln6j
17 Dec 18
Departure of Directors or Certain Officers
4:45pm
8-K
14v3tpi8 4gu
10 Dec 18
Regulation FD Disclosure
4:52pm
8-K
blzkeo
9 Nov 18
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2018 Financial Results
12:00am
8-K
nvvn s2apf2
1 Nov 18
Constellation Pharmaceuticals Receives FDA Fast Track Designation forCPI-0610 in Treatment of Myelofibrosis
7:12am
8-K
5m1vbt2d1hezx2 n22
11 Oct 18
Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study ofCPI-0610 in Myelofibrosis
12:00am
8-K
rwoau qkzm32w97
4 Sep 18
Constellation Pharmaceuticals Announces Appointments to Board of Directors
12:00am
8-K
6j3i n4llrcnj4x
14 Aug 18
Constellation Pharmaceuticals Announces Second-Quarter andSix-Month 2018 Financial Results
4:29pm